Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

First European Conference on SRS/SBRT and IG-IMRT Held in Milan



       First European Conference on SRS/SBRT and IG-IMRT Held in Milan

  PR Newswire

  SUNNYVALE, California, March 4, 2013

SUNNYVALE, California, March 4, 2013 /PRNewswire/ --

Accuray Incorporated  (Nasdaq:  ARAY ), today announced highlights from the
First European Conference on stereotactic radiosurgery/stereotactic body
radiation therapy (SRS/SBRT) and image-guided intensity-modulated radiation
therapy (IG-IMRT), hosted in partnership with the Istituto Europeo di
Oncologia Milano and the Università degli studi di Milano, held in Milan,
Italy on February 22-23, 2013.

The conference "Radiation Oncology: can we still treat without image
guidance?" was attended by more than 400 healthcare professionals, including
radiation oncologists, medical physicists and hospital administrators from 32
countries. Outcomes of recent research in areas such as central nervous system
(CNS), head and neck, breast, lung, gastrointestinal (GI), pelvis, total
marrow irradiation (TMI) and pediatrics were presented.

The independent Scientific Committee, led by Prof. Roberto Orecchia (Istituto
Europeo di Oncologia Milano, Italy) and Prof. Eric Lartigau (Centre Oscar
Lambret, Lille, France), focused on new developments in the field and
developed an educational event to discuss the need of image guidance for a
variety of clinical indications in modern radiation therapy. "Daily image
guidance is crucial for all high-precision treatments, also for palliative
treatments" said Prof. Eric Lartigau.

"The TomoTherapy® System provides an automatic process that makes our daily
work easy" said Prof. Dirk Verellen, UZ Brussel.

Prof. Ben Heijmen, Erasmus MC-Daniel den Hoed Cancer Center of Rotterdam, said
"Additionally, dose to the healthy tissue can be strongly reduced using
optimal and numerous non-coplanar beams when treating prostate cancer"
comparing non-coplanar treatments to coplanar treatments.

"There are non-adaptive and real-time adaptive solutions, but the only
solution that adapts for target motion in real-time, available clinically, is
the CyberKnife® System", added Dr. Iciar Santa Olalla.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range
of radiation therapy and radiosurgery treatments.

Safe Harbor Statement Statements made in this press release that are not
statements of historical fact are forward-looking statements and are subject
to the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this press release relate, but are
not limited, to clinical applications, clinical results, patient outcomes, and
the Company's leadership position in radiation oncology innovation.
Forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially from expectations, including risks
detailed from time to time under the heading "Risk Factors" in the company's
report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Qs
filed on November 8, 2012 & February 6, 2013, and as updated periodically by
our other filings. Forward-looking statements speak only as of the date the
statements are made and are based on information available to the Company at
the time those statements are made and/or management's good faith belief as of
that time with respect to future events. The Company assumes no obligation to
update forward-looking statements to reflect actual performance or results,
changes in assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.
 Accordingly, investors should not place undue reliance on any forward-looking
statements.

Contacts

Anja Kleber Marketing Director Tél +33(0)1-55-23-20-20 akleber@accuray.com

Sophie BaumontEdelman Paris Tél +33(0)1-56-69-75-94 sophie.baumont@edelman.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement